Lineage Cell Therapeutics, Inc. (LCTX) Earnings Call Analysis

AMEX · Healthcare · Biotechnology

10/25

Growth 2 Margin 1 Expansion 4 Platform 1 Financial 2

latest quarter score

Earnings Reports

10
Lineage Cell Therapeutics (LCTX) Q2 2026: Cash Runway Extends to 2028 on Platform-Driven Pipeline Momentum
August 07, 2026
12
Lineage Cell Therapeutics (LCTX) Q1 2026: Alloscope Platform Drives Expansion, $53M Cash Extends Runway
May 13, 2026
12
Lineage Cell Therapeutics (LCTX) Q4 2025: Oprogen Clinical Sites Up 100% as Pipeline Optionality Expands
March 06, 2026
11
Lineage Cell Therapeutics (LCTX) Q3 2025: Oprigen Clinical Sites Surge 8x, Accelerating Platform Expansion
November 07, 2025
11
Lineage Cell Therapeutics (LCTX) Q2 2025: $14.8M Non-Cash Impairment Spotlights Pipeline Refocus and Platform Leverage
August 12, 2025
11
Lineage Cell Therapeutics (LCTX) Q1 2025: Manufacturing Scale-Up Enables Multi-Program Platform Expansion
May 13, 2025
9
Lineage Cell Therapeutics (LCTX) Q4 2024: $36M Milestone-Linked Warrants Signal Confidence Amid Clinical Progress
March 10, 2025

Browse all companies